Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Oragenics, Inc.

## Sitemaps

- [XML Sitemap](https://oragenics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://oragenics.com/15c42-web-agency-gb-news/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
- [All you need to know about childhood illnesses](https://oragenics.com/6-home-remedies-for-white-teeth/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed tu istuc dixti bene Latine, parum plane. Hoc etsi multimodis reprehendi potest, tamen accipio, quod dant. Duo Reges: constructio interrete. Quasi vero, inquit, perpetua oratio rhetorum solum, non etiam philosophorum sit. Iis igitur est difficilius satis facere, qui se Latina scripta dicunt contemnere. Id mihi magnum
- [Broken hand - diagnosis and treatment](https://oragenics.com/remedies-from-grandmother-white-and-beautiful-teeth-with-pantry-products/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed quanta sit alias, nunc tantum possitne esse tanta. Itaque eos id agere, ut a se dolores, morbos, debilitates repellant. Quae cum essent dicta, finem fecimus et ambulandi et disputandi. Quem si tenueris, non modo meum Ciceronem, sed etiam me ipsum abducas licebit. Duo Reges: constructio interrete.
- [Preparing for surgery? What you need to know](https://oragenics.com/top-5-medicines-that-you-should-have-in-your-home/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Omnia peccata paria dicitis. Re mihi non aeque satisfacit, et quidem locis pluribus. Quamquam te quidem video minime esse deterritum. Qui ita affectus, beatum esse numquam probabis; Duo Reges: constructio interrete. Multoque hoc melius nos veriusque quam Stoici. Atque ego: Scis me, inquam, istud idem sentire, Piso,

## Pages

- [Home](https://oragenics.com/) - Transforming Concussion Care with Innovative Intranasal Delivery The first potential FDA-approved therapy for concussion. Oragenics is pioneering brain-first neurotherapeutics, developing ONP-002—a first-in-class intranasal neurosteroid that targets the biology of brain injury, not just the symptoms. With Phase 1 complete and Phase 2 trials underway, we’re advancing toward a new standard of care for the 69 million people who suffer concussions each year. Learn
- [Publications](https://oragenics.com/publications/) - Publications Peer-Reviewed Publications Scientific and clinical research featuring Oragenics leadership and technology, published in peer-reviewed journals. Military Medicine | July 7, 2026 | Commentary Making the Invisible Wounds of War Visible Brian L. Edlow, MD; VADM (Ret) Timothy G. Szymanski; CMSgt (Ret) Gregory A. Smith; HON (Ret) Frank J. Larkin; James P. Kelly, MA, MD;
- [Board of Directors](https://oragenics.com/board-of-directors/) - Board of Directors The Oragenics board brings together financial, regulatory, operational, and strategic leadership — with significant public company and life sciences experience. This is a board built for accountability, execution, and the governance demands of a clinical-stage, publicly traded company. Charles L. Pope Chairman of the Board Charles Pope serves as Chairman of the Oragenics Board of Directors, bringing a
- [News & Media](https://oragenics.com/news-media/) - News & Media Press Releases July 7, 2026 Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling Oragenics advances ONP-002 with full Australian trial enrollment and a new FDA engagement milestone. May 7, 2026 Oragenics Signs Letter of Intent to License CardioDialysis™ Technology Company announces letter of intent
- [Why Invest](https://oragenics.com/investor-overview/) - Why Invest A CNS Platform Built to Define a Category. Oragenics is building a proprietary central nervous system drug delivery platform — one that solves the most fundamental problem in neurological medicine: getting therapeutics directly to the brain, faster and more effectively than any existing approach. Our lead asset, ONP-002, is the first pharmacological treatment
- [Science & Technology](https://oragenics.com/science-technology/) - Science & Technology The Science of Getting There First Every drug in development faces the same fundamental challenge: getting the right molecule to the right place in the body, at the right time. For neurological conditions, that challenge is especially acute — the brain is one of the most protected organs in the human body,
- [Scientific Advisors](https://oragenics.com/scientific-advisors/) - Scientific Advisors Oragenics' scientific advisory is anchored by its Chief Medical Officer, Dr. James P. Kelly — one of the country's leading authorities on traumatic brain injury. For Dr. Kelly's full biography, see the Management Team page. James P. Kelly, MA, MD, FAAN, FANA Chief Medical Officer One of the nation's foremost authorities on traumatic
- [Management Team](https://oragenics.com/management-team/) - Management Team Our leadership combines deep neuroscience expertise, public company experience, and a relentless focus on execution. The team that leads Oragenics has spent their careers solving complex healthcare challenges — and they joined this company because they believe concussion treatment is the defining medical problem of our time. Janet Huffman Chief Executive Officer & Chief Financial Officer
- [Contact Us](https://oragenics.com/contact-us/) - Contact Us Investor Relations irth Communications 📧 ir@oragenics.com 📞 1-866-976-4784 🏛 NYSE American: OGEN Access Investor Portal Media Relations irth Communications 📧 media@irthcommunications.com 📞 1-866-976-4784 General Inquiries Stock Information Exchange NYSE American Ticker Symbol OGEN SEC Filings View on EDGAR View Investor Presentation Read Latest News
- [Overview](https://oragenics.com/15c42-web-agency-gb-overview/) - Overview Who We Are Oragenics is a clinical-stage pharmaceutical company pioneering intranasal delivery of neurological therapeutics. With a focus on conditions that have historically lacked effective treatments—beginning with mTBI (concussion) — we're building a platform to address some of the most challenging problems in brain health. Today, there is no FDA-approved pharmacological treatment for concussion.
- [Sitemap](https://oragenics.com/sitemap/) - Sitemap Pharmaceuticals ONP-002: Brain Related Drug Development Technology & Pipeline Pipeline Science & Technology News & Media News & Media Investors Why Invest Investor Presentation About Overview Management Team Board of Directors Scientific Advisors Contact Us Legal Privacy Policy Disclaimer Sitemap
- [Disclaimer](https://oragenics.com/disclaimer/) - Disclaimer Last updated: June 2026 Forward-Looking Statements This website contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management's current beliefs, assumptions, and information available at the time of publication. Forward-looking statements may be identified by words such
- [Privacy Policy](https://oragenics.com/privacy-policy/) - Privacy Policy Last updated: June 2026 Overview Oragenics, Inc. ("Oragenics," "we," "us," or "our") is committed to protecting your privacy. This Privacy Policy explains how we collect, use, and safeguard information you provide when visiting oragenics.com. Information We Collect We collect only the information you voluntarily provide when subscribing to our email updates: your first
- [ONP-002](https://oragenics.com/onp-002/) - ONP-002: Breakthrough Treatment for Concussion The First Potential FDA-Approved Treatment for Concussion ONP-002 is a first-in-class intranasal neurosteroid designed to address the underlying biology of brain injury — not just the symptoms. With Phase 1 complete and Phase 2 trials underway, we are advancing toward a new standard of care for the 69 million people
- [Pipeline](https://oragenics.com/pipeline/) - Pipeline Development Pipeline Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 ONP-002 Concussion / mTBI ✓ ✓ Active — Phase 1 Complete Safe and well-tolerated across all dose levels; zero serious adverse events Phase 2a Active 40-patient randomized, placebo-controlled trial underway in Australia Platform Technology: Beyond ONP-002 While ONP-002 leads our pipeline for concussion
- [Presentation Deck](https://oragenics.com/presentation-deck/) - Investor Presentation Spring 2026 | NYSE American: OGEN Download PDF Contact Investor Relations For more information: ir@oragenics.com
- [Pharmaceuticals](https://oragenics.com/pharma/) - Home/Pharmaceuticals Who We Are Oragenics is a clinical-stage pharmaceutical company pioneering intranasal delivery of neurological therapeutics. With a focus on conditions that have historically lacked effective treatments—beginning with concussion and mild traumatic brain injury (mTBI)—we're building a platform to address some of the most challenging problems in brain health. Today, there is no FDA-approved pharmacological
- [Investors](https://oragenics.com/investors/) - Who We Are Oragenics is a clinical-stage pharmaceutical company pioneering intranasal delivery of neurological therapeutics. With a focus on conditions that have historically lacked effective treatments—beginning with concussion and mild traumatic brain injury (mTBI)—we're building a platform to address some of the most challenging problems in brain health. Today, there is no FDA-approved pharmacological treatment
- [My account](https://oragenics.com/my-account/) - [woocommerce_my_account]
- [Checkout](https://oragenics.com/checkout/)
- [Cart](https://oragenics.com/cart/) - You may be interested in… Your cart is currently empty! New in store
- [Shop](https://oragenics.com/shop/)
- [Home](https://oragenics.com/home/) - Welcome to Neve Doctors Clinic Experience top quality in medical care by friendly and experience doctors and staff. Your one-stop for family care Book an appointment Flexible appointments Family Care We offer very efficient family care plans and packages, get in touch for an initial consultation and offer. Family Care We offer very efficient family
- [Blog](https://oragenics.com/blog/)
- [Our Clinic](https://oragenics.com/our-clinic/) - Our Clinic Latest technologies Lorem ipsum dolor sit amet, consectetur adipiscing elit. Portenta haec esse dicit, neque ea ratione ullo modo posse vivi. Duo Reges constructio interrete. Utrum igitur tibi litteram videor an totas paginas commovere. General family care A physician, medical practitioner, medical doctor, or simply doctor, is a professional who practises medicine, which
- [Portfolio Single](https://oragenics.com/15c42-web-agency-gb-portfolio-single/) - James Joyce How we helped James Joyce get a brand-consistent website that converts visitors into clients. Our goal was to create a website for James Joyce that not only reflected his brand’s personality but also effectively converted visitors into clients. By focusing on a clean, user-friendly design integrated with James’s unique brand elements, we ensured
- [Portfolio](https://oragenics.com/15c42-web-agency-gb-portfolio/) - Portfolio Buzz Website A vibrant digital platform designed to engage and inform, delivering seamless user experiences across devices. PROJECT DETAILS Branding for Chatoue Innovative branding solutions that articulate Chatoue's unique value, enhancing their market presence visually and conceptually. PROJECT DETAILS IMB Internal Website A secure and intuitive internal portal developed to streamline communication and workflow

## Categories

- [Uncategorized](https://oragenics.com/category/uncategorized/)